IQVIA Holdings Inc. (NYSE:IQV) Stake Boosted by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 8.7% in the 1st quarter, Holdings Channel reports. The firm owned 91,955 shares of the medical research company’s stock after acquiring an additional 7,382 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in IQVIA were worth $16,212,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. American National Bank & Trust bought a new position in shares of IQVIA during the first quarter valued at approximately $26,000. Golden State Wealth Management LLC grew its holdings in shares of IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 130 shares during the last quarter. AllSquare Wealth Management LLC bought a new position in shares of IQVIA during the first quarter valued at approximately $33,000. ST Germain D J Co. Inc. grew its holdings in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 76 shares during the last quarter. Finally, GKV Capital Management Co. Inc. bought a new position in shares of IQVIA during the fourth quarter valued at approximately $39,000. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. decreased their price objective on IQVIA from $232.00 to $177.00 and set an “overweight” rating for the company in a report on Monday, May 19th. Truist Financial increased their price objective on IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a report on Wednesday, July 23rd. Evercore ISI increased their price objective on IQVIA from $170.00 to $180.00 and gave the stock an “outperform” rating in a report on Wednesday, July 9th. Barclays increased their price objective on IQVIA from $165.00 to $185.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 23rd. Finally, Mizuho increased their price objective on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Seven investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $228.62.

Insiders Place Their Bets

In other news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company’s stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Price Performance

Shares of NYSE:IQV opened at $194.41 on Wednesday. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88. The stock has a fifty day moving average of $159.17 and a 200-day moving average of $170.16. The company has a market capitalization of $33.05 billion, a PE ratio of 28.13, a price-to-earnings-growth ratio of 2.17 and a beta of 1.30. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter in the prior year, the firm earned $2.64 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.